Results: 4

1.
Figure 3

Figure 3. From: Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Time to leukemic transformation of patients randomized to the SC alone (arm A, n = 57) and EPO/G-CSF (arm B, n = 53) arms. No statistically significant difference in time to transformation between these 2 groups of patients was demonstrated (P = .83).

Peter L. Greenberg, et al. Blood. 2009 September 17;114(12):2393-2400.
2.
Figure 4

Figure 4. From: Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Cumulative incidence of leukemic transformation, with death as a competing risk event. No statistically significant difference in time to transformation between these 2 groups of patients was demonstrated when the competing risk of death was included (P = .34, cumulative incidence analysis).

Peter L. Greenberg, et al. Blood. 2009 September 17;114(12):2393-2400.
3.
Figure 1

Figure 1. From: Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Overall survival of patients randomized to the supportive care alone (arm A, n = 57) and EPO/G-CSF (arm B, n = 53) arms. No statistically significant difference in overall survival between these 2 groups of patients was demonstrated (P = .28).

Peter L. Greenberg, et al. Blood. 2009 September 17;114(12):2393-2400.
4.
Figure 2

Figure 2. From: Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Forest plot of hazard ratios (EPO/SC) for overall survival related to treatment for clinical subgroups. A univariate Cox proportional hazard model, stratified on randomization features, estimated hazard ratios, and significance for overall survival. The horizontal lines provide the 95% confidence interval for the ratios. The dotted vertical line represents the overall hazard ratio (0.77).

Peter L. Greenberg, et al. Blood. 2009 September 17;114(12):2393-2400.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk